pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

395 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1031Endpoints781BioPharma Dive298BioSpace216Fierce Biotech207onclive165raps78globenewswire health
therapy area
allOncology6078Rare Disease1447Cardiology1094Hematology1028Immunology1007Vaccines907Pulmonology
  • Oncology experience not always required for pharma jobs, recruiters say
    Two recruiters say that while oncology experience can help, it is not the sole factor biopharma companies consider when hiring for oncology roles. They note that business stage, relationships and s…
    BioSpace · 23d agoNeutral↗ source
  • Vesa Pylvänäinen sells 117 Vaisala shares at €57 each
    Vaisala Corporation reported a share disposal by one of its senior managers, Vesa Pylvänäinen. On July 24, 2026, Pylvänäinen sold 117 of the company’s A‑shares at a price of €57 per share, resulti…
    globenewswire health · 22d agoRegulatoryNeutral↗ source
← prev
page 11 of 16
next →
73
fda recalls44
fda medwatch41
fda press28
905
Psychiatry & CNS724
Ophthalmology421
Endocrinology & Metabolism384
Pain376
Infectious Disease357
  • Nokia senior manager Mikko Hautala buys 7,103 shares at €7.84 each
    Nokia reported an insider transaction filed under market abuse regulation article 19. The filing lists Mikko Hautala, identified as "Other senior management", as the reporting person. On July 29,…
    globenewswire health · 22d agoCRLNeutral↗ source
  • Vaisala senior executive Vesa Pylvänäinen sells 117 shares at €57 each on Nasdaq Helsinki
    Vaisala Oyj announced that senior executive Vesa Pylvänäinen has disposed of company shares. The transaction was executed on July 24, 2026 and involved 117 ordinary shares at an average price of €…
    globenewswire health · 22d agoNeutral↗ source
  • Nokia senior manager Kristen Pressner purchases 66,324 shares at €7.84 each
    On July 29, 2026, Nokia Corporation disclosed that senior manager Kristen Pressner acquired shares of the company. The transaction involved 66,324 Nokia shares purchased at an average price of €7.…
    globenewswire health · 22d agoNeutral↗ source
  • Nokia senior manager Mikko Hautala buys 7,103 shares at €7.84 each
    Nokia Corporation disclosed that senior manager Mikko Hautala purchased 7,103 shares of the company on July 29, 2026. The transaction was reported under Article 19 of the EU Market Abuse Regulation…
    globenewswire health · 22d agoRegulatoryNeutral↗ source
  • FDA finds Replimune's melanoma data package uninterpretable, foreshadows tough advisory committee review
    The FDA has deemed the single-arm mid-stage study submitted by Replimune for its oncolytic immunotherapy RP1 as not interpretable, raising concerns ahead of an upcoming advisory committee meeting.…
    BioSpace · 24d agoRegulatoryNegative↗ source
  • Apnimed targets up to $160 million IPO to fund sleep‑apnea drug AD109
    Apnimed, a sleep‑specialist biotech, announced plans for an initial public offering that could raise up to $160 million in gross proceeds. The company will sell 10 million shares at $14‑$16 each,…
    BioSpace · 24d agoDealPositive↗ source
  • Pharma deals in China face heightened IP risk under U.S. BIOSECURE Act
    Pharma companies are increasing licensing activity in China, but experts say patent attorneys must now factor in the geopolitical implications of the BIOSECURE Act. The legislation seeks to compil…
    BioSpace · 24d agoRegulatoryNegative↗ source
  • GSK launches $2.5 billion restructuring plan to fund late-stage pipeline and offset upcoming HIV drug patent loss
    GSK reported $2.4 billion in impairment charges for the second quarter and unveiled a three‑year restructuring designed to save roughly $2.5 billion. The company says the savings will be redirecte…
    BioSpace · 23d agoPositive↗ source
  • Altimmune's pemvidutide cuts heavy drinking days in Phase 2 trial
    Altimmune reported that its experimental GLP-1/GIP injection pemvidutide achieved its primary and key secondary goals in a Phase 2 study of alcohol use disorder. The double-blind trial enrolled 10…
    BioSpace · 24d agoPositive readoutPositive↗ source
  • Oak Hill Bio to go public via SPAC merger, securing $175 million for Angelman syndrome program
    Oak Hill Bio announced it will become a publicly traded company through a merger with the special purpose acquisition company Research Alliance Corporation III. The transaction will provide $75 mi…
    BioSpace · 24d agoDealPositive↗ source
  • Industry urges FDA to clarify and broaden QSP guidance for first-in-human dose selection
    Industry stakeholders have asked the U.S. Food and Drug Administration for more detailed guidance on using quantitative systems pharmacology (QSP) to select first-in-human doses in phase-1 studies.…
    raps · 24d agoRegulatoryNeutral↗ source
  • FDA draft guidance seeks clearer, more flexible QSP dose selection for first-in-human trials
    Industry groups have asked the FDA for more clarity in a draft guidance that outlines how sponsors can use quantitative systems pharmacology (QSP) to select doses for first-in-human studies. The r…
    raps · 24d agoRegulatoryNeutral↗ source
  • Webinar Explores AI-Driven Intelligence Engine for Optimizing Antibody, ADC and Peptide Candidates
    Drug discovery teams are grappling with an ever‑growing volume of data, and converting that data into actionable insight remains a key hurdle. In a recent BioSpace webinar, Patsnap’s Ben Coverdale…
    BioSpace · 23d agoNeutral↗ source
  • WHO publishes first interim list of 12 medical device regulators eligible for WHO-listed authority status
    The World Health Organization has released its first interim list of medical device regulators that can attain WHO-listed authority status. The list names 12 regulators from different regions that…
    raps · 24d agoRegulatoryNeutral↗ source
  • OKYO Pharma CSO Raj Patil boosts stake to 20,030 shares
    OKYO Pharma, a clinical stage biotech focused on neuropathic corneal pain and anterior segment eye diseases, disclosed that its chief scientific officer, Raj Patil, PhD, bought additional shares.…
    globenewswire health · 24d agoDealNeutral↗ source
  • Danske Bank reports share sell-off by APMH Invest under ongoing buy-back program
    Danske Bank A/S disclosed recent transactions made by persons required to report under the EU Market Abuse Regulation. The notification dated 28 July 2026 notes that APMH Invest A/S has been conti…
    globenewswire health · 24d agoRegulatoryNeutral↗ source
  • DSV A/S manager files share transaction report
    DSV A/S disclosed a manager's transaction in its shares via Company Announcement No. 1172. The filing, typical for insider reporting, indicates that a senior executive or board member bought or so…
    globenewswire health · 24d agoRegulatoryNeutral↗ source
  • Danske Bank reports senior staff transactions on July 28, 2026
    Danske Bank A/S released a brief notice on July 28, 2026 indicating that transactions involving its senior employees have been disclosed. The announcement provides only the fact of the disclosure…
    globenewswire health · 24d agoNeutral↗ source
  • Otsuka receives FDA approval for Simtriyo, first norepinephrine-dopamine-serotonin reuptake inhibitor for ADHD
    Otsuka Pharmaceutical announced that the FDA has approved its daily pill centanafadine, branded as Simtriyo, for the treatment of attention-deficit hyperactivity disorder in patients six years and…
    BioSpace · 25d agoApprovalPositive↗ source
  • FDA says Capricor's DMD cell therapy failed to meet Phase 3 endpoints
    The FDA briefing documents released before an advisory committee meeting state that the Phase 3 trial of Capricor's deramiocel did not achieve its pre-specified primary and secondary efficacy endpo…
    BioSpace · 24d agoRegulatoryNegative↗ source
  • Sarepta appoints former AbbVie R&D chief Michael Severino as new CEO amid DMD regulatory outlook
    Sarepta Therapeutics announced that Michael Severino, who previously led Tessera Therapeutics and served as AbbVie’s head of research and development, will become the company’s chief executive. Sev…
    BioSpace · 25d agoPositive↗ source
  • Argenx to acquire Forte Biosciences for $2.2 billion, adding anti-CD122 antibody FB102
    Argenx announced it will buy Texas‑based Forte Biosciences in a transaction valued at roughly $2.2 billion. The offer of $77 per share represents an 86 % premium to Forte’s recent average price. T…
    BioSpace · 25d agoDealPositive↗ source
  • Denmark's foundation-driven biotech surge pulls Swedish startups across the Øresund, outpacing Nordic peers
    Denmark, and in particular its capital Copenhagen, is emerging as the leading biotech hub in the Nordic region, outpacing its neighbours in investment and talent development. Swedish biotech start…
    BioSpace · 25d agoPositive↗ source